Evidence map›Paper›PMID 41613106›Full record

ArticleFrontiers in immunology2025

Fc-enhanced anti-CCR6 antibody elicits robust therapeutic effects across multiple autoimmune diseases.

Md Jahangir Alam, Yu-Anne Yap, Caroline Ang, Liang Xie, Hillary L Shane, Charles R Mackay, Remy Robert

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Md Jahangir AlamDepartment of Physiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Yu-Anne YapDepartment of Physiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Caroline AngDepartment of Physiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Liang XieDepartment of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Hillary L ShaneDragonfly Therapeutics, Waltham, MA, United States.
Charles R MackayDepartment of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Remy RobertDepartment of Physiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation of the chemokine receptor CCR6 orchestrates the trafficking of IL-17-producing pathogenic immune cells to the sites of inflammation, thus contributing to the development of numerous inflammatory and autoimmune diseases. As such, CCR6 has emerged as a promising therapeutic target for treating Th17-mediated inflammatory disorders. In this study, we employed a targeted strategy, which we termed 'immunological surgery', using an Fc-engineered anti-human CCR6 monoclonal antibody (αhCCR6 DLE-mut mAb) designed to engage effector mechanisms against CCR6

Indexed as

Antibodies, MonoclonalAutoimmune DiseasesImmunoglobulin Fc FragmentsReceptors, CCR6AnimalsDisease Models, AnimalFemaleHumansMicePsoriasisTh17 CellsAntibodies, MonoclonalCCR6 protein, humanImmunoglobulin Fc FragmentsReceptors, CCR6arthritisCCR6IL-17Ainflammationmonoclonal antibody (mAb)psoriasissclerodermaTh17 cells

Identifiers

PMID41613106
PMCPMC12847933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.